We are live on ! Find out more
NVIV

InVivo Therapeutics Holdings Corp
NVIV

Delisted

NVIV was delisted on the 12th of February, 2024.

Back to rankings

9 hedge funds and large institutions have $144K invested in InVivo Therapeutics Holdings Corp in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 9 → 9 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

43% less capital invested

Capital invested by funds: $252K → $144K (-$108K)

Holders
9
Holders Change
–
Holders Change %
0%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WS
Wedbush Securities
California
+$52.8K
2
Northern Trust
Northern Trust
Illinois
+$18.9K
3
UBS Group
UBS Group
Switzerland
+$3.22K
4
Bank of America
Bank of America
North Carolina
+$37
5
Wells Fargo
Wells Fargo
California
+$37

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$147K
2
Two Sigma Investments
Two Sigma Investments
New York
-$25K
Name Holding Trade Value Shares
Change 		Change in
Stake
WS
1
Wedbush Securities
California
$116K +$52.8K +1,429 +78%
Northern Trust
2
Northern Trust
Illinois
$18K +$18.9K +510 New
UBS Group
3
UBS Group
Switzerland
$9K +$3.22K +87 +53%
BlackRock
4
BlackRock
New York
$1K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
– -$147K -3,729 Closed
Two Sigma Investments
6
Two Sigma Investments
New York
– -$25K -631 Closed
Bank of America
7
Bank of America
North Carolina
– +$37 +1 +100%
Wells Fargo
8
Wells Fargo
California
– +$37 +1 New

NVIV Hedge Fund Activity: Q3 2020 in Review

9 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q3 2020, worth a combined $144K — down 43% from $252K a quarter earlier.

Fund positioning in NVIV was balanced in Q3 2020: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was Wedbush Securities, adding an estimated $52.8K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $147K sold.

  • 9 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q3 2020, unchanged from Q2 2020.
  • Funds reported $144K of InVivo Therapeutics Holdings Corp stock for Q3 2020, down 43% quarter-over-quarter.
  • 2 funds opened new InVivo Therapeutics Holdings Corp positions in Q3 2020 and 2 closed out, a net change of 0 holders.
  • The largest InVivo Therapeutics Holdings Corp buyer in Q3 2020 was Wedbush Securities, an estimated $52.8K added.
  • The largest InVivo Therapeutics Holdings Corp seller in Q3 2020 was Renaissance Technologies, an estimated $147K sold.

Based on aggregated 13F filings for Q3 2020.